Loading chat...
RI S2455
Bill
Status
2/6/2026
Primary Sponsor
Matthew LaMountain
Click for details
AI Summary
-
Requires all individual and group health insurance policies, hospital service corporations, medical service corporations, and HMOs to cover FDA-approved scalp cooling systems for cancer patients undergoing chemotherapy, effective January 1, 2027
-
Scalp cooling systems are defined as FDA-approved medical devices that cool the scalp to prevent or reduce chemotherapy-induced hair loss (alopecia) before, during, or after treatment
-
Exempts limited benefit policies from the mandate, including hospital confinement indemnity, disability income, accident only, long-term care, Medicare supplement, and specified disease indemnity plans
-
Takes effect upon passage, with coverage requirements applying to policies delivered, issued, or renewed on or after January 1, 2027
Legislative Description
Mandates insurance coverage for scalp cooling treatments for cancer patients undergoing chemotherapy to prevent hair loss during chemotherapy treatments.
Insurance
Last Action
Introduced, referred to Senate Health and Human Services
2/6/2026